Drug Profile
Research programme: bispecific antibodies - Genmab/Janssen Biotech
Alternative Names: Ab 957; BCMAxCD3 bispecific antibody; EM1-mAb DuoBodyLatest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Genmab; Janssen Biotech
- Developer Genmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor modulators; Immunomodulators; Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in Denmark (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology